These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 30784875

  • 1. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
    Song XQ, Ma ZY, Wu YG, Dai ML, Wang DB, Xu JY, Liu Y.
    Eur J Med Chem; 2019 Apr 01; 167():377-387. PubMed ID: 30784875
    [Abstract] [Full Text] [Related]

  • 2. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 6. Pt(IV) Prodrugs with NSAIDs as Axial Ligands.
    Spector D, Krasnovskaya O, Pavlov K, Erofeev A, Gorelkin P, Beloglazkina E, Majouga A.
    Int J Mol Sci; 2021 Apr 07; 22(8):. PubMed ID: 33917027
    [Abstract] [Full Text] [Related]

  • 7. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
    Zanellato I, Bonarrigo I, Colangelo D, Gabano E, Ravera M, Alessio M, Osella D.
    J Inorg Biochem; 2014 Nov 07; 140():219-27. PubMed ID: 25171667
    [Abstract] [Full Text] [Related]

  • 8. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
    Qiao X, Gao YY, Zheng LX, Ding XJ, Xu LW, Hu JJ, Gao WZ, Xu JY.
    Eur J Med Chem; 2021 Nov 05; 223():113730. PubMed ID: 34388483
    [Abstract] [Full Text] [Related]

  • 9. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 10. Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen †.
    Ravera M, Zanellato I, Gabano E, Perin E, Rangone B, Coppola M, Osella D.
    Int J Mol Sci; 2019 Jun 24; 20(12):. PubMed ID: 31238499
    [Abstract] [Full Text] [Related]

  • 11. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

  • 12. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 13. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 14. Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo.
    Song XQ, Liu RP, Wang SQ, Li Z, Ma ZY, Zhang R, Xie CZ, Qiao X, Xu JY.
    J Med Chem; 2020 Jun 11; 63(11):6096-6106. PubMed ID: 32401032
    [Abstract] [Full Text] [Related]

  • 15. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 16. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P, Bang S, Yue Z, Beach T, Stilgenbauer M, Wang H, Bowers DJ, Kurokawa M, Xiao H, Zheng YR.
    Dalton Trans; 2020 Jun 23; 49(24):8107-8113. PubMed ID: 32490446
    [Abstract] [Full Text] [Related]

  • 17. Ketoplatin in triple-negative breast cancer cells MDA-MB-231: High efficacy and low toxicity, and positive impact on inflammatory microenvironment.
    Ma ZY, Song XQ, Hu JJ, Wang DB, Ding XJ, Liu RP, Dai ML, Meng FY, Xu JY.
    Biochem Pharmacol; 2021 Jun 23; 188():114523. PubMed ID: 33741331
    [Abstract] [Full Text] [Related]

  • 18. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 23; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 19. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment.
    Li Z, Qiao X, Liu XM, Shi SH, Qiao X, Xu JY.
    Eur J Med Chem; 2023 Mar 15; 250():115233. PubMed ID: 36863224
    [Abstract] [Full Text] [Related]

  • 20. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H, Noble GT, Stefanick JF, Qi R, Kiziltepe T, Jing X, Bilgicer B.
    J Control Release; 2014 Jan 10; 173():11-7. PubMed ID: 24511610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.